Previous Article | Next Article 
Molecular and Cellular Biology, September 2001, p. 6170-6180, Vol. 21, No. 18
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.18.6170-6180.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
A Point Mutation in the N-Terminal Coiled-Coil
Domain Releases c-Fes Tyrosine Kinase Activity and Survival Signaling
in Myeloid Leukemia Cells
Haiyun Y.
Cheng,
Anthony P.
Schiavone, and
Thomas E.
Smithgall*
Department of Molecular Genetics and
Biochemistry, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania 15261
Received 8 May 2001/Accepted 27 June 2001
 |
ABSTRACT |
The c-fes locus encodes a 93-kDa non-receptor protein
tyrosine kinase (Fes) that regulates the growth and differentiation of
hematopoietic and vascular endothelial cells. Unique to Fes is a long
N-terminal sequence with two regions of strong homology to coiled-coil
oligomerization domains. We introduced leucine-to-proline substitutions
into the coiled coils that were predicted to disrupt the coiled-coil
structure. The resulting mutant proteins, together with
wild-type Fes, were fused to green fluorescent protein and expressed in
Rat-2 fibroblasts. We observed that a point mutation in the first
coiled-coil domain (L145P) dramatically increased Fes tyrosine kinase
and transforming activities in this cell type. In contrast, a similar
point mutation in the second coiled-coil motif (L334P) was without
effect. However, combining the L334P and L145P mutations reduced
transforming and kinase activities by approximately 50% relative to
the levels of activity produced with the L145P mutation alone. To study
the effects of the coiled-coil mutations in a biologically relevant
context, we expressed the mutant proteins in the granulocyte-macrophage
colony-stimulating factor (GM-CSF)-dependent myeloid leukemia cell line
TF-1. In this cellular context, the L145P mutation induced GM-CSF
independence, cell attachment, and spreading. These effects correlated
with a marked increase in L145P protein autophosphorylation relative to
that of wild-type Fes. In contrast, the double coiled-coil mutant
protein showed greatly reduced kinase and biological activities in TF-1
cells. These data are consistent with a role for the first coiled coil
in the negative regulation of kinase activity and a requirement for the
second coiled coil in either oligomerization or recruitment of
signaling partners. Gel filtration experiments showed that the unique
N-terminal region interconverts between monomeric and oligomeric forms.
Single point mutations favored oligomerization, while the double point
mutant protein eluted essentially as the monomer. These data provide
new evidence for coiled-coil-mediated regulation of c-Fes tyrosine
kinase activity and signaling, a mechanism unique among tyrosine kinases.
 |
INTRODUCTION |
The human c-fes
proto-oncogene encodes a 93-kDa non-receptor protein tyrosine kinase
(Fes) with strong expression in myeloid hematopoietic cells. Fes has
been implicated in signal transduction pathways for several
hematopoietic cytokines, including interleukin-3 (IL-3), IL-4, IL-6,
granulocyte-macrophage colony-stimulating factor (GM-CSF), and
erythropoietin (reviewed in reference 37). Other evidence
suggests that Fes may contribute to differentiation signaling from
cytokine receptors. For example, expression of Fes in the human myeloid
leukemia cell line K-562 results in growth suppression and terminal
differentiation (4, 40). More recent work suggests that
interaction with Bcr-Abl may be responsible for Fes activation in this
chronic myelogenous leukemia (CML)-derived cell line, implicating Fes
as a suppressor of CML progression as well (19). On the
other hand, inhibition of Fes expression with antisense
oligonucleotides blocks differentiation of HL-60 cells and triggers an
apoptotic response instead (24). These results implicate
Fes in both differentiation and survival signaling pathways in myeloid leukocytes.
The c-Fes protein consists of three distinct structural domains: a long
unique N-terminal region, a central SH2 domain, and a C-terminal kinase
domain (37). Fes lacks an SH3 domain, a negative
regulatory tail tyrosine residue, and other structural features that
contribute to the negative regulation of Src, Abl, and other
non-receptor protein tyrosine kinases. However, like Src and Abl, Fes
tyrosine kinase activity is tightly regulated in mammalian cells and
induces little or no transforming activity upon ectopic expression in
rodent fibroblasts (6, 8). The mechanism responsible for
negative regulation of Fes tyrosine kinase activity in vivo is not clear.
One unique aspect of c-Fes structure is the presence of coiled-coil
homology domains in the unique N-terminal region (4, 33).
Coiled coils are composed of amphipathic
-helices that exhibit a
heptad repeat pattern in which the first and fourth positions are
occupied by hydrophobic amino acids (21). These residues
align to form a hydrophobic interface between the supercoiled strands.
Previous work from our laboratory has shown that the N-terminal region
of Fes mediates its oligomerization in vitro, suggesting that
interconversion of monomeric and oligomeric forms of the protein may
regulate kinase activity in vivo. Consistent with this idea is our
finding that overexpression of the isolated Fes N-terminal region can
suppress the kinase and transforming activities of a full-length Fes
mutant protein that is activated by membrane targeting. The suppressive
effect may involve formation of an inactive heteromer comprised of
full-length and truncated strands (4, 33).
In this study, we provide evidence that the Fes coiled-coil homology
domains are required for both negative regulation and full activation
of kinase function. We observed that a single point mutation of a key
leucine residue in the first coiled-coil (CC1) domain results in strong
kinase activation in vivo, leading to potent transforming activity in
fibroblasts as well as survival and differentiation signaling in
myeloid cells. Interestingly, when the activating mutation in CC1 is
combined with a similar point mutation in the second coiled coil (CC2),
tyrosine kinase and biological activities are significantly impaired,
suggesting that CC2 may be required for mediating Fes oligomerization
or downstream signaling in vivo. Gel filtration experiments show that
the unique N-terminal region can adopt monomeric and oligomeric forms,
suggesting that the coiled coils regulate kinase activity by
controlling the oligomerization state of the protein. Use of coiled-coil domains is unique among non-receptor protein tyrosine kinases as a regulatory mechanism.
 |
MATERIALS AND METHODS |
Construction of Fes coiled-coil point mutant
proteins.
Residues essential for coiled-coil structure were
determined using the COILS algorithm (23) (see Fig.
1) and include Leu 145 in the CC1 domain and Leu 334 in the CC2 domain.
These leucine residues were converted to proline using an Altered Sites
mutagenesis kit according to the instructions of the manufacturer
(Promega). Both individual-mutation (L145P, L334P) and double-mutation
(2LP) proteins were created. The presence of each mutation was
confirmed by automated DNA sequence analysis.
Construction of GFP-Fes fusion proteins.
To create green
fluorescent protein (GFP)-Fes expression constructs, the enhanced GFP
coding sequence was amplified from the vector pEGFP-C1 (Clontech) by
PCR and subcloned into the retroviral expression vector
pSR
MSVtkneo (27) to create plasmid
pSR
-GFP. The cDNA clones encoding wild-type Fes, the coiled-coil
domain point mutant proteins, and the other forms of Fes used in this study were subcloned downstream and in frame with GFP in this vector.
Production of recombinant retroviruses.
Recombinant
retroviruses were produced by cotransfecting 293T cells with the
pSR
-GFP-Fes constructs described above and either ecotropic or
amphotropic packaging vectors as described elsewhere (2, 4,
18). A GFP retrovirus was prepared from the pSR
-GFP parent
vector for use as a negative control. Retroviral supernatants were
collected every 12 h for 3 days, and the pooled supernatants were
aliquoted and stored at
80°C.
Retroviral infection of Rat-2 fibroblasts and focus-forming
assay.
Rat-2 cells were obtained from the American Type Culture
Collection and maintained in Dulbecco's modified Eagle's medium
supplemented with 5% fetal bovine serum. Cells were plated in six-well
plates (2 × 105 cells per well) 1 day prior to
infection. Retroviral stocks (4 ml) were thawed on ice, supplemented
with Polybrene to 4 µg/ml, and added to the cells. The plates
were centrifuged at 1,500 × g for 3 h at room
temperature to enhance the efficiency of infection. The virus was
replaced with fresh medium, and the infected cells were incubated for
48 h at 37°C prior to being plated in transformation assays.
For focus-forming assays, infected cells (2 × 104)
were plated in 60-mm-diameter dishes in the presence of 800 µg
of G418 per ml. The culture medium was changed every second or third
day for 14 days. Transfomed foci were stained with Wright-Giemsa stain and counted from a scanned image using a Bio-Rad GS-710 calibrated imaging densitometer and Quantity One software.
Expression of Fes coiled-coil mutant proteins in TF-1 myeloid
leukemia cells.
The human myeloid leukemia cell line TF-1
(17) was obtained from the American Type Culture
Collection and cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 50 µg of gentamicin per ml, and 1 ng of GM-CSF
(BioSource International) per ml. Recombinant retroviruses for TF-1
cell infection were prepared using the 293T cell protocol described
above, except that an amphotropic packaging plasmid was used. For TF-1
cell infection, 2 × 105 cells were plated in each
well of a six-well plate and centrifuged at 500 × g
for 15 min. The medium was aspirated and replaced with the retroviral
supernatant plus Polybrene, and the infection protocol was continued as
described above for the Rat-2 cells. Following infection, the cells
were placed under G418 selection for 10 to 14 days. Expression of GFP
or the GFP-Fes fusion proteins was confirmed by fluorescence
microscopy, under which the drug-resistant cell population exhibited
uniform green fluorescence. Expression of full-length GFP-Fes fusion
proteins was also confirmed by immunoblotting (see below).
To monitor GM-CSF dependence, 2 × 10
5 cells were
washed free of GM-CSF and plated in duplicate six-well plates. GM-CSF
(1 ng/ml)
was added to one plate, and viable cells were counted
following
trypan blue staining every 2 days until saturation density
was
reached.
For attachment experiments, 5 × 10
4 cells were plated
in duplicate 24-well plates in a total volume of 1 ml in the presence
or absence of GM-CSF. Cells were returned to the incubator for
5 to 7 days and fixed in situ with cold acetone-methanol (1:1)
for 5 min prior
to fluorescence microscopy to confirm c-Fes expression.
Alternatively,
cells were directly stained with Giemsa stain and
visualized by light
microscopy. The number of attached cells in
three randomly chosen
fields was counted, and the results were
averaged. Data are presented
as percentages of attached cells
observed relative to the number of
attached cells of the GFP-Fes
L145P mutant protein, which gave the
strongest
response.
Analysis of Fes protein expression and autophosphorylation.
Aliquots of Rat-2 or TF-1 cells were pelleted, washed with
phosphate-buffered saline, and lysed in 1 ml of
radioimmunoprecipitation assay (RIPA), buffer (50 mM Tris-HCl [pH
7.4], 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate
[SDS], 1 mM EDTA, and 1% sodium deoxycholate). Fes proteins were
immunoprecipitated from clarified cell lysates using either the M2
anti-FLAG monoclonal antibody resin (Sigma) or an anti-GFP antibody
(Clontech) and protein G-Sepharose (Pharmacia). Immunoprecipitates were
washed with RIPA buffer, resolved by SDS-polyacrylamide gel
electrophoresis (PAGE), and immunoblotted for Fes expression with the
anti-FLAG antibody or for phosphotyrosine content with the
antiphosphotyrosine monoclonal antibody PY99 (Santa Cruz).
Gel filtration analysis of the Fes N-terminal region.
The
coding sequence of the Fes N-terminal region encompassing both
coiled-coil motifs (Ala 91 to Gly 392; CC1+2) was amplified from
wild-type and coiled-coil mutant Fes templates by PCR and subcloned
into the baculovirus transfer vector pVL-GFP. The pVL-GFP vector was
constructed by PCR amplification of the enhanced GFP coding sequence
from pEGFP-C1 (Clontech) and subcloning downstream of the polyhedrin
promoter. The resulting vectors were used to produce recombinant
baculoviruses using Baculogold DNA (PharMingen) and the manufacturer's
protocol. For gel filtration experiments, the GFP-Fes CC1+2 fusion
proteins were expressed in Sf-9 insect cells and lysates were prepared
by sonication in 1.0 ml of S-300 buffer (50 mM Tris-HCl [pH 7.4], 50 mM NaCl, 1 mM EDTA). Lysates were clarified by centrifugation at
100,000 × g for 1 h and applied to a Sephacryl
S-300 column (1.6 by 77 cm) previously equilibrated with S-300 buffer.
Fractions (0.25 ml) were collected directly in 96-well microtiter
plates, and the elution profile of each GFP-CC1+2 fusion protein was
determined by fluorescence detection using a SpectraMax Gemini XS
fluorimetric microplate reader (Molecular Devices, Inc.). As an
additional control, unfused GFP was run alone and found to be
monomeric. Peak fractions were pooled and concentrated, and the
presence of the GFP-CC1+2 fusion protein was verified by immunoblotting
with anti-GFP antibodies (Clontech).
 |
RESULTS |
Identification of N-terminal residues critical for
coiled-coil structure.
Coiled-coil domains are characterized by a
heptad repeat of amino acids often denoted a-b-c-d-e-f-g, with
hydrophobic residues at positions a and d (21). The
hydrophobic residues pack against each other to form the supercoil
interface, while polar residues generally occupy the other positions
and interact with solvent. Analysis of the Fes sequence with the COILS
algorithm (22) predicts two regions with a high
probability of coiled-coil structure formation within the Fes
N-terminal region (33) (Fig.
1). Using COILS, we identified Leu
residues that occupy a central d position within each predicted coiled
coil and appear to be critical for the integrity of the coiled-coil
structure. As shown in Fig. 1, replacement of Leu 145 with Pro in the
first coiled-coil motif reduced the probability of coiled-coil
formation from nearly 100% to less than 40%. A similar Pro
substitution for Leu 334 within the second coiled-coil region nearly
abolished the predicted coiled-coil formation. These substitutions were
introduced into the full-length c-Fes coding region either alone or in
combination. The proteins with the resulting coiled-coil mutations
(L145P, L334P, and 2LP) were fused to GFP in a retroviral vector for
expression in fibroblasts and human myeloid progenitor cells. The
structures of these Fes proteins and the other constructs used in this
study are shown in Fig. 2.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Identification of Fes N-terminal residues essential for
coiled-coil formation. Wild-type and mutant forms of the 822-amino-acid
Fes sequence were analyzed using the COILS algorithm. The probability
of each residue contributing to coiled-coil formation is plotted as a
function of its position within the overall sequence. The mutant
proteins include one with a proline substitution for Leu 145 in the CC1
domain (L145P) protein, one with a proline substitution for Leu 334 in
the CC2 domain (L334P protein), and a double mutant protein with both
substitutions (2LP). For this analysis, a 28-residue sliding window was
used along with the MTIDK matrix. For additional details, see
http://www.ch.embnet.org/software/COILS_form.html. WT, wild
type.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
GFP-Fes constructs used in this study. The structure of
the wild-type GFP-Fes fusion protein is shown at the top and includes a
unique N-terminal region, an SH2 domain, and a C-terminal kinase
domain. The locations of the two coiled-coil homology regions are
indicated as the shaded boxes (CC1 and CC2). Mutant proteins include
one with a proline substitution for Leu 145 in the first coiled-coil
domain (L145P), one with a proline substitution for Leu 334 in the CC2
domain (L334P), and the corresponding double mutant protein with both
substitutions (2LP). We also constructed GFP fusion proteins of the
CC1 and CC2 deletion mutant proteins and the corresponding
kinase-inactive forms of these proteins ( CC1-KE, CC2-KE). All
constructs have a C-terminal FLAG epitope tag (not shown).
|
|
Proline substitution for d-position leucine residues in the Fes
coiled-coil domains have opposing actions on tyrosine kinase activity
in Rat-2 fibroblasts.
Previous studies have shown that wild-type
c-Fes is nontransforming and that its tyrosine kinase activity is
highly repressed following expression in Rat-2 fibroblasts, providing a
convenient system to study the contribution of Fes structural features
to the negative regulation of kinase activity (4, 8).
Using recombinant retroviruses, the Fes coiled-coil domain point mutant proteins were expressed in Rat-2 fibroblasts as GFP fusion proteins. The GFP-Fes proteins were immunoprecipitated, and kinase activity was
analyzed in terms of autophosphorylation by antiphosphotyrosine immunoblotting. As shown in Fig. 3,
wild-type GFP-Fes tyrosine autophosphorylation was very low in this
system, indicative of negative regulation as observed previously.
However, proline substitution for Leu 145 within the CC1 domain
enhanced autophosphorylation by more than 10-fold, indicating that the
CC1 domain is required for negative regulation of kinase activity in
vivo. Proline substitution for Leu 334 in the CC2 domain did not affect
kinase activity relative to that of wild-type GFP-Fes. However, this
same substitution reduced the kinase activity of the L145P mutant
protein by more than 50%, suggesting that an intact CC2 domain is
required for efficient autophosphorylation in vivo.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Autophosphorylation of GFP-Fes proteins in Rat-2
fibroblasts. Rat-2 fibroblasts stably expressing each of the GFP-Fes
constructs shown in Fig. 2 were lysed, and GFP-Fes fusion proteins were
precipitated with the M2 anti-FLAG monoclonal antibody. (A)
Immunoprecipitates were washed with RIPA buffer, resolved by SDS-PAGE,
and immunoblotted for Fes expression with the anti-FLAG antibody (Fes)
or for phosphotyrosine content with the antiphosphotyrosine monoclonal
antibody PY99 (P-Tyr). A representative blot is shown. (B) The
experiment was repeated three times, and the relative levels of GFP-Fes
protein and phosphotyrosine content were quantitated using an imaging
densitometer. Ratios of tyrosine autophosphorylation to Fes protein
were calculated and are presented as means ± standard deviations.
KE, kinase-inactive form.
|
|
We next compared the activities of these point mutant proteins to those
of coiled-coil deletion mutant proteins previously
described by members
of our laboratory (
4). We observed that
a GFP-Fes deletion
mutant protein lacking the CC1 domain (GFP-

CC1)
exhibited
approximately 80% of the kinase activity of the GFP-L145P
mutant protein (Fig.
3). Addition of a kinase-inactivating mutation
abolished GFP-

CC1 protein autophosphorylation, indicating that
CC1
deletion affects Fes kinase activity directly. Interestingly,
deletion
of the CC2 domain resulted in a slight increase in tyrosine
phosphorylation, an effect that was also dependent upon the intact
kinase domain. These results, as well as those obtained with the
point
mutant proteins, are consistent with a model in which CC1-CC2
interaction contributes to negative regulation by holding the
kinase in
an inactive conformation (see
Discussion).
The Fes CC1 domain point mutant protein exhibits strong
transforming activity in Rat-2 cells.
Results presented in the
previous section show that disruption of the CC1 domain with a
Leu-to-Pro substitution releases Fes kinase activity in vivo. To
determine whether this mutant protein retains the capacity to generate
a biological signal, we compared its transforming activity with those
of wild-type Fes and the other coiled-coil domain mutant proteins.
Rat-2 fibroblasts were infected with recombinant Fes retroviruses and
placed under G418 selection for 2 weeks, at which time the foci were
stained and counted. As shown in Fig. 4
and 5, the wild-type GFP-Fes fusion protein did not exhibit focus-forming activity, consistent with earlier
studies of wild-type c-Fes (4, 8, 18). However, the L145P
mutant protein exhibited very potent focus-forming activity, consistent
with the effect of this mutation on Fes autophosphorylation. In
contrast, proline substitution for Leu 334 in the CC2 domain did not
release transforming activity. Combining the CC1 and CC2 mutations
reduced focus-forming activity by more than 50% relative to that of
the L145P single mutant protein. The focus-forming activities of the
mutant proteins closely paralleled the relative levels of kinase
activity (Fig. 3).

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 4.
Focus-forming activity of GFP-Fes proteins in Rat-2
fibroblasts. Rat-2 fibroblasts were infected with recombinant GFP-Fes
retroviruses as described in Materials and Methods. For focus-forming
assays, infected cells were plated in 60-mm-diameter dishes and
incubated in the presence of G418 for 14 days. Scanned images of the
stained cultures are shown, which appear as confluent monolayers with
transformed foci (where present) growing on top.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 5.
Quantitative comparison of GFP-Fes coiled-coil mutant
protein transforming activities. Each of the GFP-Fes proteins
illustrated in Fig. 2 was tested for focus-forming activity as
described in Materials and Methods and the legend to Fig. 4. Foci were
visualized by Wright-Giemsa staining and counted using a Bio-Rad model
GS-710 scanning densitometer and colony-counting software. Foci
from three independent cultures were counted; the bar graph shows
average values ± standard deviations. KE, kinase-inactive form.
|
|
Comparable transformation results were obtained with GFP fusion
proteins of the Fes CC1 and CC2 deletion mutant proteins.
GFP-Fes

CC1 protein exhibited strong focus-forming activity,
although the
number of foci observed was about 50% of that observed
with the L145P
mutant protein (Fig.
5). Transforming activity
was not observed with
the kinase-defective GFP-

CC1 mutant protein,
indicating that
transformation is directly dependent upon an active
c-Fes kinase domain
and is not the result of endogenous kinase
activation. Interestingly,
deletion of the CC2 domain caused a
slight increase in GFP-Fes
transforming activity, consistent with
the autophosphorylation
result.
The Fes CC1 domain point mutant protein generates signals for
survival and attachment in myeloid leukemia cells.
Previous
studies have suggested that Fes may transduce signals for
differentiation and survival in response to cytokines or other upstream
signals (37). To determine whether the Fes CC1 domain
point mutant protein can generate signals in a physiological context,
we expressed this mutant protein in the myeloid leukemia cell line
TF-1. This cell line requires GM-CSF for growth and differentiates into
macrophage-like cells in response to phorbol esters (17).
Wild-type GFP-Fes as well as each of the coiled-coil domain mutant
proteins were introduced into TF-1 cells using recombinant retroviruses
along with GFP alone as a negative control. Infected cell populations
were selected in the presence of G418 and GM-CSF, and uniform
expression of the transduced proteins in each of the infected cell
populations was verified by fluorescence microscopy (data not shown).
To determine whether expression of the Fes coiled-coil point mutant
proteins affected the requirement of TF-1 cells for cytokine, levels of
growth of the infected cell populations were compared in the presence
and absence of GM-CSF. As shown in Fig. 6, no proliferation was observed in cells
expressing wild-type GFP-Fes or GFP alone. However, cells expressing
the Fes protein with the CC1 domain point mutation (L145P) grew rapidly
in the absence of cytokine, providing direct evidence that Fes kinase activity is sufficient to generate a signal for survival and
proliferation in myeloid cells. Interestingly, the protein with point
mutations in both CC domains was unable to generate this response,
suggesting that similar mechanisms regulate Fes activity in myeloid
cells and upon ectopic expression in fibroblasts. All of the cell
populations grew rapidly in the presence of GM-CSF. The protein with
the CC2 domain point mutation (L334P) was unable to support
cytokine-independent proliferation of TF-1 cells, consistent with the
fibroblast result (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Cytokine-independent survival and proliferation of TF-1
myeloid leukemia cells expressing the GFP-Fes CC1 domain point mutant
protein. TF-1 cells were infected with recombinant retroviruses
carrying GFP as a negative control (open bars), GFP-Fes (gray bars),
GFP-Fes L145P protein (hatched bars), or GFP-Fes 2LP (solid bars).
Following infection, the cells were placed under G418 selection in the
presence of GM-CSF for 10 to 14 days, at which point each of the
drug-resistant cell populations exhibited uniform green fluorescence
(data not shown). To monitor GM-CSF dependence, cells were washed free
of cytokine and replated in the absence (top panel) or presence (bottom
panel) of GM-CSF and viable cells were counted following trypan
blue staining every 2 days. Two independent experiments yielded
comparable results.
|
|
In addition to cytokine-independent survival, we observed that a
significant subpopulation of TF-1 cells expressing the CC1
point mutant
protein attached to the culture plate and spread
to form
macrophage-like cells (Fig.
7). These
cells also expressed
cell-surface CD13 and CD33, which are myeloid
differentiation
markers induced by Fes in other cell lines (
4,
34; data not
shown). This effect was unique to the GFP-Fes L145P
protein, as
cells expressing GFP alone, wild-type GFP-Fes, the CC2
point mutant
protein, or the CC1+2 mutant protein did not attach or
spread.
We also investigated the effect of GM-CSF on the adherence of
each of the TF-1 cell populations (Fig.
8). Adherent cells appeared
more rapidly
in the presence of GM-CSF, reaching a maximum at
5 days. In addition, a
low attachment response was observed with
GM-CSF-treated cells
expressing wild-type Fes or the coiled-coil
domain mutant proteins but
not with GFP alone. These results suggest
that Fes may transduce
signals for morphological aspects of differentiation
downstream of the
GM-CSF receptor.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 7.
A point mutation in the GFP-Fes CC1 domain induces
attachment and spreading of TF-1 myeloid leukemia cells. TF-1 cells
were infected with a recombinant GFP retrovirus or the indicated
GFP-Fes retroviruses and selected as described in the legend to Fig. 6.
Following selection, the cells were replated in 24-well plates in the
presence of GM-CSF and returned to the incubator for 5 days. Cells were
stained in situ with Giemsa stain and visualized by light microscopy.
Phase-contrast images of TF-1 cells expressing GFP, GFP-Fes, GFP-Fes
L334P, and GFP-2LP were recorded under low-power magnification (×100).
Images of cells expressing the GFP-Fes CC1 domain point mutant (L145P)
protein were recorded under low-power (middle left panel) and
high-power (×400; middle right panel) magnification.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 8.
Quantitative comparison of the effects of GFP-Fes CC
domain mutant proteins on TF-1 cell morphology in the presence and
absence of GM-CSF. TF-1 cells were infected with a recombinant GFP
retrovirus or the indicated GFP-Fes retroviruses and selected as
described in the legend to Fig. 6. For attachment experiments, 5 × 104 cells were plated in duplicate 24-well plates in the
presence (+) or absence ( ) of GM-CSF. Cells were returned to the
incubator for 5 days (open bars) or 7 days (shaded bars), stained with
Giemsa stain, and visualized by light microscopy. The number of
attached cells was counted in three randomly chosen fields, and results
are presented as average values ± standard deviations. This
entire experiment was performed twice and produced the same pattern of
responses in each case.
|
|
We also examined the tyrosine kinase activity of wild-type Fes and the
coiled-coil domain mutants in the context of TF-1 cell
expression. Fes
proteins were immunoprecipitated and kinase activity
was evaluated in
terms of autophosphorylation on antiphosphotyrosine
immunoblots. As
shown in Fig.
9, autophosphorylation of
both wild-type
Fes and the CC2 domain point mutant protein was
undetectable.
In contrast, the CC1 point mutant protein exhibited a
very high
level of autophosphorylation in both the presence and the
absence
of GM-CSF. Addition of the L334P mutation in the CC2 domain
substantially
reduced the kinase activity of GFP-Fes L145P protein.
These results
correlate with both the survival and the differentiation
responses
in TF-1 cells and with the transforming and kinase activities
of these mutant proteins in the fibroblast transformation assay,
although the suppressive effect of the L334P mutation is more
pronounced in TF-1 cells (see Discussion).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 9.
Autophosphorylation of GFP-Fes CC domain mutant proteins
in TF-1 myeloid cells. TF-1 cells stably expressing each of the GFP-Fes
fusion proteins indicated were washed free of GM-CSF and incubated in
the presence or absence of cytokine for 48 h. Cells were collected
by centrifugation and lysed, and GFP-Fes fusion proteins were
precipitated with the M2 anti-FLAG monoclonal antibody.
Immunoprecipitates were washed with RIPA buffer, resolved by SDS-PAGE,
and immunoblotted for Fes expression with the anti-FLAG antibody (Fes)
or for phosphotyrosine content with the antiphosphotyrosine monoclonal
antibody PY99 (P-Tyr). This experiment was repeated twice and produced
comparable results in each case; a representative blot is shown.
|
|
Analysis of the wild-type and mutant Fes coiled-coil regions by gel
filtration.
Data presented here and in our previous studies
indicate that the Fes N-terminal coiled-coil domains may control Fes
kinase activity by regulating the oligomerization state of the protein (4, 33). To investigate the effects of the coiled-coil
domain point mutations on N-terminal oligomerization, we performed a series of gel filtration experiments. For these experiments, wild-type and mutant Fes N-terminal sequences encompassing both coiled-coil motifs (Ala 91 to Gly 392) were expressed as GFP fusion proteins in
Sf-9 insect cells. Each GFP-CC1+2 fusion protein was then resolved on a
Sephacryl S-300 gel filtration column, and 288 fractions were collected
for each sample in 96-well plates. The positions of the GFP-CC1+2
fusion proteins in the elution profiles were determined as the relative
fluorescence intensity of each well. As shown in Fig.
10, the wild-type
GFP-CC1+2 fusion protein eluted as a mixture of monomeric and
oligomeric forms. The peak intensities of the monomer (peak 1) and
major oligomer (peak 3) were approximately equal. The monomer (peak 1)
eluted with an apparent molecular mass lower than expected (40 kDa
observed versus 52 kDa calculated), which may reflect a tight
conformation of the protein. However, SDS-PAGE shows that this peak is
full-length GFP-CC1+2 (see below). The major oligomer (peak 3) eluted
with a mass of approximately 300 kDa, consistent with at least a
pentamer; a similar result was observed previously for full-length Fes
as well as the complete N-terminal region (33). At least
one additional intermediate form was apparent (peak 2), suggesting that
Fes can form multiple oligomeric structures. This result provides the
first evidence that the Fes coiled-coil region can exist as a monomer
and suggests that it can interconvert between monomeric and oligomeric
states. Note that GFP itself elutes as a single symmetrical peak,
consistent with a monomer, indicating that it does not contribute to
oligomer formation (data not shown). The position of GFP in the
chromatogram is indicated at the top of Fig. 10.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 10.
Analysis of N-terminal-Fes-GFP fusion proteins by gel
filtration. Recombinant fusion proteins of GFP and Fes N-terminal amino
acids encoding the CC1 and CC2 domains as well as the intervening
sequence were expressed in Sf-9 cells. Cells were lysed by sonication,
and lysates were clarified by ultracentrifugation and applied to a
Sephacryl S-300 column. Fractions (0.25 ml) were collected in 96-well
plates and analyzed for fluorescence using a microplate reader. Four
fusion proteins were examined, and the resulting fluorescence elution
profiles are shown together with an illustration of each protein. From
top to bottom these include wild-type GFP-Fes CC1+2, the CC1 point
mutant (L145P) protein, the CC2 point mutant (L334P) protein, and the
double mutant protein. The void volume was determined independently
using blue dextran, which eluted as a single peak at the position
indicated as Vo (fraction 134). All fractions that appeared
before the blue dextran peak were devoid of fluorescence and are
omitted for clarity. Unfused GFP was also run as a control; it eluted as a single symmetrical peak, the position of which
is indicated at the top (fraction 242). The following standards, with
their molecular masses and elution positions noted, were also run:
thyroglobulin, 634 kDa, fraction 149; ferritin, 439 kDa, fraction 165;
catalase, 200 kDa, fraction 185; aldolase, 178 kDa, fraction 189;
albumin, 62 kDa, fraction 202; ovalbumin, 48 kDa, fraction 207; and
chymotrypsinogen A, 21 kDa, fraction 246. The entire experiment was
repeated twice and produced the same pattern of fluorescent peaks for
each protein. Note that the absolute levels of fluorescence varied less
than twofold among the four fusion proteins.
|
|
The GFP-CC1+2 fusion protein with the CC1 point mutation (L145P) showed
a dramatic shift from the monomeric to multiple oligomeric
forms,
including the peak 2 and peak 3 forms observed with wild-type
Fes CC1+2
as well as an additional oligomer of higher molecular
weight (peak 4).
This result shows that the L145P mutation promotes
oligomerization of
the N-terminal region and is consistent with
the hypothesis that this
mutation activates Fes in vivo by disrupting
intramolecular CC1-CC2
interaction and allowing oligomerization
through CC2 (see
Discussion).
Mutation of the CC2 domain (L334P) within GFP-CC1+2 also favored
oligomerization, almost exclusively to the peak 3 form. This
result
also supports the model of intramolecular CC1-CC2 interaction
as a
mechanism for the suppression of kinase activity in vivo.
In this case,
oligomerization may be driven by the wild-type CC1
domain. However, the
full-length L334P mutant protein lacks activity
both in fibroblasts and
in TF-1 cells, suggesting that a wild-type
CC2 domain is essential for
kinase activity and/or interaction
with signaling partners in vivo (see
Discussion).
We also investigated the oligomerization status of a GFP-CC1+2 fusion
protein with point mutations in both coiled-coil domains.
The double
mutant protein eluted almost exclusively as the monomer
(peak 1). This
finding suggests that the full-length Fes double
mutant protein may be
impaired in its capacity to oligomerize,
which may account in part for
its reduced biological and kinase
activities both in fibroblasts and in
TF-1 myeloid
cells.
To verify that each of the fluorescent peaks observed in Fig.
10
corresponds to a GFP-CC1+2 fusion protein, peak fractions
were pooled,
concentrated, and analyzed by immunoblotting with
anti-GFP antibodies.
As shown in Fig.
11, all of the peaks
contained
GFP-immunoreactive bands of identical apparent molecular
weights
consistent with the expected size of the GFP-CC1+2 fusion
protein.
This result shows that the different peaks observed upon gel
filtration
reflect different oligomeric states of the Fes N-terminal
protein.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 11.
Immunoblot analysis of GFP-Fes CC1+2 fusion proteins
following gel filtration. Peak fractions from Sephacryl S-300
chromatography of the GFP-Fes CC1+2 fusion proteins shown in Fig. 10
were pooled, concentrated, and resolved by SDS-PAGE. The proteins were
transferred to polyvinylidene difluoride membranes and probed with an
antibody to GFP. Results are shown for wild-type GFP-Fes CC1+2 (WT),
the CC1 mutation (L145P) protein, the CC2 mutation (L334P) protein, and
the double mutant protein (2LP). The numbers above each lane refer to
the major peaks shown in Fig. 10.
|
|
 |
DISCUSSION |
Cooperation of the CC1 and CC2 domains in the regulation of c-Fes
tyrosine kinase activity.
Previous studies have shown that c-Fes
and the closely related tyrosine kinase Fer exhibit several motifs with
strong coiled-coil homology in their unique N-terminal regions
(5, 16, 33). In c-Fes, the N-terminal region has been
shown to mediate oligomerization of the kinase, leading to
autophosphorylation by a trans mechanism (33,
35). These findings suggest that Fes oligomerization may be
required for autophosphorylation of Tyr 713 within the activation loop,
a prerequisite for kinase activation both in vitro and vivo (13,
35). In this report, we provide evidence demonstrating opposing
actions of the coiled-coil domains in the regulation of Fes tyrosine
kinase activity in vivo. Proline substitution for Leu 145 in the more
N-terminal coiled-coil domain released Fes tyrosine kinase activity in
Rat-2 fibroblasts, leading to transformation. This result suggests that
the CC1 domain primarily serves a negative regulatory function, a
conclusion consistent with our earlier work demonstrating that CC1
deletion can enhance the transforming and tyrosine kinase activities of
a membrane-targeted form of c-Fes (4). The activating
effect of the L145P mutation was reversed when combined with a proline
substitution for Leu 334 in the more C-terminal region of coiled-coil
homology. This result indicates that the CC2 domain is required for
full kinase activation. Given its close proximity to the SH2 and kinase
domains, the CC2 domain may act to align the kinase domains in an
orientation favoring efficient trans phosphorylation within
the active oligomer. Interestingly, deletion of the CC2 domain within
GFP-Fes resulted in a small increase in kinase activity in fibroblasts,
suggesting that the CC1 domain may partially complement the loss of CC2
(Fig. 3).
How does the CC1 domain act to repress Fes tyrosine kinase activity?
One possibility is that it interacts intramolecularly
with the CC2
domain, thereby repressing CC2-mediated formation
of the active
oligomer. The results of gel filtration experiments
(Fig.
10 and
11)
support this possibility. A GFP fusion protein
with the N-terminal
region encompassing both coiled coils was
found to exist as a mixture
of monomeric and oligomeric forms.
The major wild-type GFP-CC1+2
oligomer elutes with an apparent
molecular mass of about 300 kDa, which
suggests that it forms
at least a pentamer. This finding is consistent
with the results
of previous gel filtration experiments using
full-length Fes as
well as the isolated N-terminal region
(
33). Mutation of either
CC1 or CC2 favored the elution of
oligomers at the expense of
the monomer, supporting the existence of
CC1-CC2 interactions
in the monomer. However, only the L145P mutant
protein is active
in cells, suggesting that oligomers formed by the
L334P mutant
protein are not compatible with kinase activation or
signaling
function. Interestingly, when point mutations were introduced
into both coiled-coils, the GFP-CC1+2 fusion protein eluted as
a
monomer. This result suggests that the reduced kinase activity
of the
full-length double mutant protein may be due to a reduced
oligomerization capacity in vivo. Whether or not CC1-CC2 interaction
occurs within the context of full-length inactive Fes will require
structural
analysis.
The L145P mutation in the CC1 domain represents the first
gain-of-function mutation described for Fes that is independent
of an
artificial membrane-targeting signal. However, N-terminal
fusion of
these mutant proteins to GFP is very important for stabilizing
their
expression in Rat-2 fibroblasts. Although a Fes L145P mutant
protein
without GFP could be transiently expressed in 293T cells
and exhibited
very high levels of tyrosine kinase activity relative
to that of the
wild-type kinase (data not shown), attempts to
produce lines of Rat-2
cells that stably express this mutant were
unsuccessful. The mechanism
by which fusion to GFP allows for
stabilization is unknown. One
possibility is that this modification
protects the active kinase from
ubiquitination or other pathways
for degradation. In this regard,
active forms of Src have recently
been shown to undergo
ubiquitin-mediated degradation (
10,
12).
Fes activation is sufficient for survival and differentiation
signaling in myeloid cells.
Identification of an activated mutant
enabled us to investigate the signaling function of Fes in a
physiologically relevant cell type. The cell line used for this study
was TF-1, a myeloid leukemia cell line that retains a cytokine
requirement for growth and survival (17). Expression of
the L145P mutant protein of Fes resulted in cytokine-independent
proliferation of TF-1 cells, providing evidence that Fes may activate
downstream signaling pathways that regulate cellular survival. These
results are consistent with earlier work using v-Fps, a
transforming retroviral homolog of c-Fes, and other tyrosine kinase
oncogenes (25, 30). In addition, constitutive activation
of Fes as a result of the L145P mutation caused attachment and
spreading of TF-1 cells, consistent with previous work implicating Fes
in the terminal differentiation of myeloid leukemia cells (4, 34,
40). Both the survival and differentiation effects of the L145P
mutation were almost completely reversed in the double mutant protein
(2LP), suggesting that an intact CC2 domain is required for efficient
kinase activation or downstream signaling in myeloid cell types.
Interestingly, the CC2 mutation did not have as dramatic an impact on
the transforming function of the GFP-Fes L145P protein following
ectopic expression in Rat-2 cells. One implication of this difference
is that CC2-mediated interaction of Fes with a specific signaling
partner may be required for the generation of physiological signals in
myeloid cells. It also possible that cell-specific
trans-acting factors may impose more strict control on Fes
kinase activity in physiological sites of expression.
Previous studies have shown that overexpression of wild-type Fes is
sufficient to induce terminal differentiation in the myeloid
leukemia
cell line K-562 (
4,
40). These cells are derived
from the
blast crisis phase of CML and express the oncogenic tyrosine
kinase
Bcr-Abl (
20). Recently, we observed that Bcr-Abl interacts
directly with and phosphorylates Fes, suggesting that Bcr-Abl
may serve
as an upstream activator of Fes and that the differentiation
response
may be restricted to K-562 cells (
19). However, data
presented here with TF-1 cells show that Fes-induced differentiation
is
independent of the presence of Bcr-Abl. Introduction of the
activated
CC1 mutant of Fes induced a dramatic effect on TF-1
cell morphology,
promoting cell attachment and spreading (Fig.
7). We have recently
observed a similar effect in this cell line
with another activated form
of Fes in which SH2 domain specificity
has been changed to that of Src
(
34). Interestingly, activation
of Fes by either mechanism
(SH2 domain substitution or CC1 mutation)
correlates with a dramatic
subcellular redistribution of Fes,
from diffuse cytoplasmic sites to
strong focal sites both in TF-1
cells and in fibroblasts
(
34; H. Cheng and T. Smithgall, unpublished
data). Other
work has shown that overexpression of wild-type Fes
induces
phosphorylation of p130 Cas and other proteins associated
with cell
adhesion and cell-cell contact in macrophages (
1,
15).
These results suggest that Fes may regulate morphological
aspects of
differentiation by targeting proteins involved in adhesion-related
processes.
Constitutive activation of the Fes tyrosine kinase may promote TF-1
cell survival and morphological differentiation through
a number of
downstream signal transduction pathways. One possibility
is Stat3,
which is a direct substrate for Fes and associates with
Fes in response
to GM-CSF treatment (
29,
31). Strong support
for a
Fes-Stat3 connection comes from studies of mice engineered
to express
kinase-defective Fes in place of the wild-type locus
through
gene-targeting techniques (
36). GM-CSF was unable to
induce activation of Stat3 in macrophages from these animals,
implying
a nonredundant role for Fes in Stat3 activation downstream
of the
GM-CSF receptor. In contrast, Stat3 activation is enhanced
in cells
from
fes homozygous null animals, suggesting that the
presence of the Fes protein is essential for effective control
of Stat3
signaling in vivo (
9). Stat3 has been linked to the
induction of Bcl-X
L and suppression of apoptosis in other
systems
and is required for terminal differentiation in some myeloid
leukemia
cell lines (
3,
26,
28). Fes and related
transforming oncogenes
have also been shown to activate PI3K, which is
linked to the
suppression of apoptosis via the Akt kinase (
7,
14). A final
possibility involves activation of the small
GTPases Ras, Rac,
and Cdc42. Activation of all three of these small
GTPases is required
for transformation of Rat-2 fibroblasts by
activated forms of
Fes (
18). Rac and Cdc42 directly
regulate the actin cytoskeleton
and may contribute to the observed
effects of Fes on TF-1 cell
attachment and spreading reported here
(
11,
38). In addition,
constitutive activation of the
Ras-mitogen-activated protein kinase
pathway is sufficient to induce
differentiation of myeloid leukemia
cells and other cell types
(
32,
39). Future experiments will
address the signaling
pathways responsible for Fes-induced survival
and differentiation
responses in TF-1
cells.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the National
Institutes of Health (CA 58667) and the American Cancer Society
(RPG-96-052-04-TBE).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of
Medicine, E1240 Biomedical Science Tower, Pittsburgh, PA 15261. Phone:
(412) 648-9495. Fax: (412) 624-1401. E-mail:
tsmithga{at}pitt.edu.
 |
REFERENCES |
| 1.
|
Areces, L. B.,
P. D. Sbarba,
M. Jucker,
E. R. Stanley, and R. A. Feldman.
1994.
Functional specificity of cytoplasmic and transmembrane tyrosine kinases: identification of 130- and 75-kilodalton substrates of c-fps/fes tyrosine kinase in macrophages.
Mol. Cell. Biol.
14:4606-4615[Abstract/Free Full Text].
|
| 2.
|
Briggs, S. D.,
M. Sharkey,
M. Stevenson, and T. E. Smithgall.
1997.
SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1.
J. Biol. Chem.
272:17899-17902[Abstract/Free Full Text].
|
| 3.
|
Catlett-Falcone, R.,
T. H. Landowski,
M. M. Oshiro,
J. Turkson,
A. Levitzki,
R. Savino,
G. Ciliberto,
L. Moscinski,
J. L. Fernández-Luna,
G. Nuñez,
W. S. Dalton, and R. Jove.
1999.
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.
Immunity
10:105-115[CrossRef][Medline].
|
| 4.
|
Cheng, H. Y.,
J. A. Rogers,
N. A. Dunham, and T. E. Smithgall.
1999.
Regulation of c-Fes tyrosine kinase and biological activities by N-terminal coiled-coil oligomerization domains.
Mol. Cell. Biol.
19:8335-8343[Abstract/Free Full Text].
|
| 5.
|
Craig, A. W.,
R. Zirngibl, and P. Greer.
1999.
Disruption of coiled-coil domains in Fer protein-tyrosine kinase abolishes trimerization but not kinase activation.
J. Biol. Chem.
274:19934-19942[Abstract/Free Full Text].
|
| 6.
|
Feldman, R. A.,
D. R. Lowy,
W. C. Vass, and T. J. Velu.
1989.
A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene.
J. Virol.
63:5469-5474[Abstract/Free Full Text].
|
| 7.
|
Fukui, Y.,
A. R. Saltiel, and H. Hanafusa.
1991.
Phosphatidylinositol-3 kinase is activated in v-Src, v-Yes, and v-Fps transformed chicken embryo fibroblasts.
Oncogene
6:407-411[Medline].
|
| 8.
|
Greer, P. A.,
K. Meckling-Hansen, and T. Pawson.
1988.
The human c-fps/fes gene product expressed ectopically in rat fibroblasts is nontransforming and has restrained protein-tyrosine kinase activity.
Mol. Cell. Biol.
8:578-587[Abstract/Free Full Text].
|
| 9.
|
Hackenmiller, R.,
J. Kim,
R. A. Feldman, and M. C. Simon.
2000.
Abnormal Stat activation, hematopoietic homeostasis, and innate immunity in c-fes / mice.
Immunity
13:397-407[CrossRef][Medline].
|
| 10.
|
Hakak, Y., and G. S. Martin.
1999.
Ubiquitin-dependent degradation of active Src.
Curr. Biol.
9:1039-1042[CrossRef][Medline].
|
| 11.
|
Hall, A.
1998.
Rho GTPases and the actin cytoskeleton.
Science
279:509-514[Abstract/Free Full Text].
|
| 12.
|
Harris, K. F.,
I. Shoji,
E. M. Cooper,
S. Kumar,
H. Oda, and P. M. Howley.
1999.
Ubiquitin-mediated degradation of active Src tyrosine kinase.
Proc. Natl. Acad. Sci. USA
96:13738-13743[Abstract/Free Full Text].
|
| 13.
|
Hjermstad, S. J.,
K. L. Peters,
S. D. Briggs,
R. I. Glazer, and T. E. Smithgall.
1993.
Regulation of the human c-fes protein-tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (tyr 713).
Oncogene
8:2283-2292[Medline].
|
| 14.
|
Izuhara, K.,
R. A. Feldman,
P. Greer, and N. Harada.
1996.
Interleukin-4 induces association of the c-fes proto-oncogene product with phosphatidylinositol-3 kinase.
Blood
88:3910-3918[Abstract/Free Full Text].
|
| 15.
|
Jucker, M.,
K. McKenna,
A. J. Da Silva,
C. E. Rudd, and R. A. Feldman.
1997.
The Fes protein-tyrosine kinase phosphorylates a subset of macrophage proteins that are involved in cell adhesion and cell-cell signaling.
J. Biol. Chem.
272:2104-2109[Abstract/Free Full Text].
|
| 16.
|
Kim, L., and T. W. Wong.
1995.
The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors.
Mol. Cell. Biol.
15:4553-4561[Abstract].
|
| 17.
|
Kitamura, T.,
T. Tange,
T. Terasawa,
S. Chiba,
T. Kuwaki,
K. Miyagawa,
Y.-F. Piao,
K. Miyazono,
A. Urabe, and F. Takaku.
1989.
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3 or erythropoietin.
J. Cell. Physiol.
140:323-334[CrossRef][Medline].
|
| 18.
|
Li, J., and T. E. Smithgall.
1998.
Fibroblast transformation by Fps/Fes tyrosine kinases requires Ras, Rac and Cdc42 and induces extracellular signal-regulated and c-Jun N-terminal kinase activation.
J. Biol. Chem.
273:13828-13834[Abstract/Free Full Text].
|
| 19.
|
Lionberger, J. M., and T. E. Smithgall.
2000.
The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Cancer Res.
60:1097-1103[Abstract/Free Full Text].
|
| 20.
|
Lozzio, B. B.,
C. B. Lozzio,
E. G. Bamberger, and A. S. Feliu.
1981.
A multipotential leukemia cell line (K-562) of human origin.
Proc. Soc. Exp. Biol. Med.
166:546-550[CrossRef][Medline].
|
| 21.
|
Lupas, A.
1996.
Coiled coils: new structures and new functions.
Trends Biochem. Sci.
21:375-382[CrossRef][Medline].
|
| 22.
|
Lupas, A.
1996.
Prediction and analysis of coiled-coil structures.
Methods Enzymol.
266:513-525[Medline].
|
| 23.
|
Lupas, A.,
M. Van Dyke, and J. Stock.
1991.
Predicting coiled coils from protein sequences.
Science
252:1162-1164[Free Full Text].
|
| 24.
|
Manfredini, R.,
A. Grande,
E. Tagliafico,
D. Barbieri,
P. Zucchini,
G. Citro,
G. Zupi,
C. Franceschi,
U. Torelli, and S. Ferrari.
1993.
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
J. Exp. Med.
178:381-389[Abstract/Free Full Text].
|
| 25.
|
Meckling-Gill, K. A.,
S. P. Yee,
J. W. Schrader, and T. Pawson.
1992.
A retrovirus encoding the v-fps protein-tyrosine kinase induces factor-independent growth and tumorigenicity in FDC-P1 cells.
Biochim. Biophys. Acta
1137:65-72[Medline].
|
| 26.
|
Minami, M.,
M. Inoue,
S. Wei,
K. Takeda,
M. Matsumoto,
T. Kishimoto, and S. Akira.
1996.
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line.
Proc. Natl. Acad. Sci. USA
93:3963-3966[Abstract/Free Full Text].
|
| 27.
|
Muller, A. J.,
J. C. Young,
A. M. Pendergast,
M. Pondel,
R. N. Landau,
D. R. Littman, and O. N. Witte.
1991.
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Mol. Cell. Biol.
11:1785-1792[Abstract/Free Full Text].
|
| 28.
|
Nakajima, K.,
Y. Yamanaka,
K. Nakae,
H. Kojima,
M. Ichiba,
N. Kiuchi,
T. Kitaoka,
T. Fukada,
M. Hibi, and T. Hirano.
1996.
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells.
EMBO J.
15:3651-3658[Medline].
|
| 29.
|
Nelson, K.,
J. A. Rogers,
T. L. Bowman,
R. Jove, and T. E. Smithgall.
1998.
Activation of STAT3 by the c-Fes protein-tyrosine kinase.
J. Biol. Chem.
273:7072-7077[Abstract/Free Full Text].
|
| 30.
|
Ostermeyer, A. G., and S. M. Anderson.
1996.
Induction of growth factor-independence and GM-CSF secretion by the v-src oncogene in murine myeloid cells does not require membrane association of pp60v-src.
Exp. Hematol.
24:176-184[Medline].
|
| 31.
|
Park, W. Y.,
J. H. Ahn,
R. A. Feldman, and J. S. Seo.
1998.
c-Fes tyrosine kinase binds to and activates STAT3 after granulocyte-macrophage colony-stimulating factor stimulation.
Cancer Lett.
129:29-37[CrossRef][Medline].
|
| 32.
|
Racke, F. K.,
K. Lewandowska,
S. Goueli, and A. N. Goldfarb.
1997.
Sustained activation of the extracellular signal-regulated kinase mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells.
J. Biol. Chem.
272:23366-23370[Abstract/Free Full Text].
|
| 33.
|
Read, R. D.,
J. M. Lionberger, and T. E. Smithgall.
1997.
Oligomerization of the Fes tyrosine kinase: evidence for a coiled-coil domain in the unique N-terminal region.
J. Biol. Chem.
272:18498-18503[Abstract/Free Full Text].
|
| 34.
|
Rogers, J. A.,
H. Y. Cheng, and T. E. Smithgall.
2000.
SH2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
Cell Growth Differ.
11:581-592[Abstract/Free Full Text].
|
| 35.
|
Rogers, J. A.,
R. D. Read,
J. Li,
K. L. Peters, and T. E. Smithgall.
1996.
Autophosphorylation of the Fes tyrosine kinase: evidence for an intermolecular mechanism involving two kinase domain tyrosine residues.
J. Biol. Chem.
271:17519-17525[Abstract/Free Full Text].
|
| 36.
|
Sensis, Y.,
R. Zirngibl,
J. McVeigh,
A. Haman,
T. Hoang, and P. A. Greer.
1999.
Targeted disruption of the murine fps/fes proto-oncogene reveals that Fps/Fes kinase activity is dispensible for hematopoiesis.
Mol. Cell. Biol.
19:7436-7446[Abstract/Free Full Text].
|
| 37.
|
Smithgall, T. E.,
J. A. Rogers,
K. L. Peters,
J. Li,
S. D. Briggs,
J. M. Lionberger,
H. Cheng,
A. Shibata,
B. Scholtz,
S. Schreiner, and N. A. Dunham.
1998.
The c-Fes family of protein-tyrosine kinases.
Crit. Rev. Oncogen.
9:43-62[Medline].
|
| 38.
|
Tapon, N., and A. Hall.
1997.
Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton.
Curr. Opin. Cell Biol.
9:86-92[CrossRef][Medline].
|
| 39.
|
Whalen, A. M.,
S. C. Galasinski,
P. S. Shapiro,
T. S. Nahreini, and N. G. Ahn.
1997.
Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase.
Mol. Cell. Biol.
17:1947-1958[Abstract].
|
| 40.
|
Yu, G.,
T. E. Smithgall, and R. I. Glazer.
1989.
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
J. Biol. Chem.
264:10276-10281[Abstract/Free Full Text].
|
Molecular and Cellular Biology, September 2001, p. 6170-6180, Vol. 21, No. 18
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.18.6170-6180.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McPherson, V. A., Everingham, S., Karisch, R., Smith, J. A., Udell, C. M., Zheng, J., Jia, Z., Craig, A. W. B.
(2009). Contributions of F-BAR and SH2 Domains of Fes Protein Tyrosine Kinase for Coupling to the Fc{varepsilon}RI Pathway in Mast Cells. Mol. Cell. Biol.
29: 389-401
[Abstract]
[Full Text]
-
Murray, M. J., Davidson, C. M., Hayward, N. M., Brand, A. H.
(2006). The Fes/Fer non-receptor tyrosine kinase cooperates with Src42A to regulate dorsal closure in Drosophila. Development
133: 3063-3073
[Abstract]
[Full Text]
-
Delfino, F. J., Stevenson, H., Smithgall, T. E.
(2006). A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer. J. Biol. Chem.
281: 8829-8835
[Abstract]
[Full Text]
-
Sangrar, W., Zirgnibl, R. A., Gao, Y., Muller, W. J., Jia, Z., Greer, P. A.
(2005). An Identity Crisis for fps/fes: Oncogene or Tumor Suppressor?. Cancer Res.
65: 3518-3522
[Abstract]
[Full Text]
-
Kanda, S., Mochizuki, Y., Nakamura, T., Miyata, Y., Matsuyama, T., Kanetake, H.
(2005). Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn. J. Cell Sci.
118: 961-970
[Abstract]
[Full Text]
-
Egelhoff, T. T., Croft, D., Steimle, P. A.
(2005). Actin Activation of Myosin Heavy Chain Kinase A in Dictyostelium: A BIOCHEMICAL MECHANISM FOR THE SPATIAL REGULATION OF MYOSIN II FILAMENT DISASSEMBLY. J. Biol. Chem.
280: 2879-2887
[Abstract]
[Full Text]
-
Laurent, C. E., Delfino, F. J., Cheng, H. Y., Smithgall, T. E.
(2004). The Human c-Fes Tyrosine Kinase Binds Tubulin and Microtubules through Separate Domains and Promotes Microtubule Assembly. Mol. Cell. Biol.
24: 9351-9358
[Abstract]
[Full Text]
-
Craig, A. W. B., Greer, P. A.
(2002). Fer Kinase Is Required for Sustained p38 Kinase Activation and Maximal Chemotaxis of Activated Mast Cells. Mol. Cell. Biol.
22: 6363-6374
[Abstract]
[Full Text]